PerkinElmer

MAY 6, 2022

One approach currently being explored involves stimulating innate immune response pathways. For example, the STimulator of InterferoN Genes (STING) pathway, which is known to play a critical role in innate immunity in response to viral and bacterial DNA, has also been shown to promote anti-tumor immune responses.

Immune Response 52

Immune Response DNA Clinical Trials Clinical Development 52

The Pharma Data

DECEMBER 13, 2020

SYNB1891 is an investigational drug for the intra-tumoral treatment of solid tumors and lymphoma, composed of an engineered Synthetic Biotic designed to activate the STING pathway in the tumor microenvironment in order to upregulate the patient’s immune response. SYNB1891 is being evaluated in a Phase 1 clinical trial.

Immune Response 40

Immune Response Treatment Engineering Clinical Trials 40

The Pharma Data

JUNE 25, 2021

To identify strains causing COVID-19 infections within the trial, sequencing of virus variants has so far been performed on 474 COVID-19 cases, of which 124 fulfilled adjudication criteria and were included in the present efficacy analysis. CureVac remains committed to COVID-19 vaccine development. About CVnCoV.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

OCTOBER 19, 2020

Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

LifeSciVC

MARCH 1, 2023

This was recently underscored by Nurix Therapeutics who presented multiple posters at the Society for Immunotherapy of Cancer Annual Meeting on their Phase One CBL-B program. And in early January, we bolstered the potential of CBL-B inhibition by announcing clearance of our first IND based on robust preclinical data.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

The Pharma Data

JANUARY 31, 2021

Delivery of viral antigens in potent vaccine vectors to elicit a strong immune response is a cornerstone of successful infectious disease vaccines,” said Karin Jooss, PhD, Executive Vice President of Research and Chief Scientific Officer of Gritstone.

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. 1 Noyce RS, et al.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

DECEMBER 27, 2020

These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Forward-Looking Statements.

Therapies 40

Therapies Clinical Trials Production Treatment 40

Agency IQ

APRIL 12, 2024

For therapeutic protein products , a critical use of assays is the detection and assessment of potential anti-drug antibody (ADA) formation, signaling a product’s potential to induce an unwanted immune response.

Production 40

Production FDA Therapies Biochemical Assays 40

Drug Target Review

JANUARY 15, 2024

An important limitation of antibodies against tumour antigens is that these agents direct responses to molecular targets present on the surface of the cell. Figure 1: HLA Class I presentation of peptides derived from intracellular antigens. However, most of these peptides may also be presented by normal cells.

Engineering 110

Engineering DNA Virus Immune Response 110

Broad Institute

OCTOBER 11, 2023

He also read everything he could about her disease, including emerging evidence that suggested that the immune system could recognize and kill Merkel cell carcinoma. His mother had a presentation of the disease that suggested her immune system was already on the job.

Research 137

Research Immune Response Clinical Trials Therapies 137

The Pharma Data

SEPTEMBER 8, 2021

executive vice president of Research and Development at Amgen. “We are pleased to present additional analyses for LUMAKRAS, our newly approved KRAS G12C inhibitor, as well as a trial-in-progress poster for acapatamab, our investigational BiTE molecule being studied in NSCLC and other solid tumors. Reese, M.D., In the U.S.,

Trials 52

Trials Clinical Trials Therapies Treatment 52

Drug Target Review

JULY 11, 2023

Spending a couple of years practicing on the wards around London, and then moving into management consulting at McKinsey & Company which led her to work in pharmaceutical research and development (R&D). Cavlan progressed to diligence work around assets and pipelines as well as building out McKinsey’s Real World Evidence practice.

Disease 75

Disease RNA Small Molecule Clinical Development 75

The Pharma Data

SEPTEMBER 8, 2021

Since immune checkpoint inhibitors were introduced more than a decade ago, they have played a transformational role in treating cancers with high unmet need, and most importantly, helping people with cancer live longer,” said Samit Hirawat, M.D. Summary of Presentations. Presentation. Abstract Title. Session Title.

Research 52

Research Immune Response Treatment Trials 52

The Pharma Data

APRIL 26, 2022

1,2 Approximately 26,000 people in the US present with advanced, unresectable HCC each year.3. The BLA for tremelimumab and sBLA for Imfinzi are based on final results from the HIMALAYA Phase III trial presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. 0.93; p=0.0035).4

Immune Response 52

Immune Response Trials Treatment Disease 52

Agency IQ

JUNE 9, 2023

However, even the most innovative in vitro assays still present major limitations when it comes to fully understanding and assessing the risks of a product. For this reason, animal models are still used both during drug discovery and the more intensive nonclinical studies conducted during clinical development.

FDA 40

FDA Science Small Molecule Immune Response 40

The Pharma Data

AUGUST 17, 2021

Results from CheckMate -648 were presented in an oral session during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and were selected for the official ASCO press program. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Treatment 52

Treatment Immune Response Trials FDA Approval 52

The Pharma Data

DECEMBER 20, 2020

“We are encouraged by the data shown in these two studies of GPS in combination with checkpoint inhibitors and look forward to additional data from these studies,” stated Dragan Cicic, MD, Senior Vice President, Clinical Development of SELLAS. “We Kenilworth, N.J.,

Immune Response 40

Immune Response Clinical Trials Therapies Trials 40

Drug Target Review

DECEMBER 28, 2023

These newly formed mutated proteins are called neoantigens and they are only present on tumour cells and are not found in normal, healthy cells. These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

The Pharma Data

OCTOBER 14, 2020

APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of APX005M to CD40 on antigen presenting cells (i.e.,

Treatment 40

Treatment Immune Response Clinical Trials Clinical Development 40

The Pharma Data

MARCH 29, 2022

The pCR data from CheckMate -816 were presented at the American Association for Cancer Research (AACR) Annual Meeting 2021, and the EFS results will be presented in a clinical trials plenary session at the AACR Annual Meeting 2022 on April 11, 2022, beginning at 10:15 a.m. CT, in New Orleans, Louisiana. About Opdivo.

Treatment 52

Treatment Clinical Trials Trials Immune Response 52

The Pharma Data

NOVEMBER 29, 2020

The webcast and the presentation will be available within the Investors & Media section of HOOKIPA’s website at [link]. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses.

Vaccine 40

Vaccine Clinical Trials Disease Therapies 40

The Pharma Data

APRIL 11, 2021

Data selected for an oral presentation in a Clinical Trials Plenary Session at the American Association for Cancer Research Annual Meeting 2021. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response.

Trials 52

Trials Treatment Clinical Trials Immune Response 52

The Pharma Data

APRIL 16, 2021

These data were presented at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. About Opdivo.

Treatment 52

Treatment Trials Clinical Trials Immune Response 52

The Pharma Data

MARCH 11, 2021

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Treatment 52

Treatment Trials Therapies FDA Approval 52

The Pharma Data

JULY 23, 2021

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Treatment 52

Treatment Trials Therapies Disease 52

The Pharma Data

AUGUST 11, 2020

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Therapies 52

Therapies Trials Disease Treatment 52

The Pharma Data

AUGUST 11, 2020

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Treatment 52

Treatment Trials Therapies Clinical Trials 52

The Pharma Data

SEPTEMBER 15, 2020

New stability, immunogenicity, and tolerability data for COVID-19 vaccine candidate, BNT162b2, presented. In the blinded data presented, 50% of trial participants received placebo and 50% received BNT162b2. Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

The Pharma Data

OCTOBER 26, 2020

Following the unauthorized download of all abstracts on the SITC website, Transgene is communicating the content of the late-breaking poster abstract that will be presented at the SITC 35th Anniversary Annual Meeting (SITC 2020), to be held virtually November 9-14, 2020. Key findings of the trial: .

Vaccine 40

Vaccine Trials Treatment Virus 40

Drug Target Review

DECEMBER 13, 2024

These types differ in their etiology, natural history, and present distinct challenges in disease management. 3,4 However, inter- and intra-tumoural heterogeneity is widespread in lung cancer, leading to multiple mechanisms through which these tumours can and do develop resistance to treatment. percent of total cancer fatalities.

Therapies 98

Therapies Treatment Clinical Trials Drugs 98

The Pharma Data

JUNE 2, 2022

Affinivax has developed the Multiple Antigen Presenting System (MAPS), a novel technology that supports higher valency than conventional conjugation technologies, enabling broader coverage against prevalent pneumococcal serotypes and potentially creating higher immunogenicity than current vaccines. About MAPSTM technology platform.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

APRIL 4, 2023

Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. Of the patients who developed pneumonitis, 54% interrupted KEYTRUDA, 63% discontinued KEYTRUDA, and 71% had resolution. Hypophysitis KEYTRUDA can cause immune-mediated hypophysitis.

Treatment 40

Treatment FDA Approval FDA Therapies 40

The Pharma Data

MAY 31, 2022

Affinivax has developed the Multiple Antigen Presenting System (MAPS), a novel technology that supports higher valency than conventional conjugation technologies, enabling broader coverage against prevalent pneumococcal serotypes and potentially creating higher immunogenicity than current vaccines. MAPS TM technology platform.

Vaccine 52

Vaccine Immune Response Clinical Trials Disease 52

The Pharma Data

NOVEMBER 12, 2020

The CALAVI trials were launched based on preclinical and early clinical evidence that Calquence could decrease the hyperinflammatory immune response and improve clinical outcomes in patients hospitalised with respiratory symptoms of COVID-19.1 The data will be presented in due course.

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52

Drug Target Review

FEBRUARY 25, 2025

These immune cells are critical to the bodys ability to mount an effective anti-tumour response. However, the use of IL-15 in cancer therapy has been limited by its short half-life and limited ability to engage the full spectrum of immune responses. This is where NKTR-255 comes into play.

Therapies 52

Therapies Immune Response Treatment Clinical Trials 52